Ligand Pharmaceuticals and Neurogen amend merger agreement
Ligand Pharmaceuticals, a biotechnology company, and Neurogen, a drug development company, have amended their merger agreement to increase the merger consideration payable.
Medicis and LipoSonix, Inc. today jointly announced they have entered into a definitive merger agreement under which Medicis will acquire LipoSonix, an independent, privately-held company with a staff of approximately 40 scientists, engineers and clinicians located near Seattle, Washington.